Clinical trials
Neovascular Age-related Macular Degeneration clinical trials
Below are recruiting neovascular age-related macular degeneration clinical trials, each written for real people, not researchers. We’re tracking 82 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05986864RecruitingPhase 1/Phase 2
Gene therapy injection for wet AMD
This study tests a new gene therapy injection called SKG0106 for people with wet AMD. The treatment is given as an injection into the eye and aims to reduce the need for frequent anti-VEGF shots.
St. Petersburg, FloridaAges 50 years+ - NCT06659445RecruitingPhase 2
Study of ONL1204 for geographic atrophy in dry AMD
This study tests an investigational medicine called ONL1204 given as an injection into the eye for people with a form of advanced dry age-related macular degeneration called geographic atrophy. The goal is to see if it can slow vision loss.
Gilbert, ArizonaAges 55 years+ - NCT07338461Recruiting
High-resolution eye imaging study for healthy and eye disease volunteers
This study uses a special, high-resolution camera to take detailed pictures of the back of the eye. It is testing the camera's ability to see changes in the retina for people who are healthy or have age-related macular degeneration, diabetic retinopathy, or other conditions that affect autofluorescence patterns.
MilanAges 18 years+ - NCT07614776RecruitingPhase 3
New Eye Injection Treatment for Age-Related Macular Degeneration
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
Fullerton, CaliforniaAges 50 years+ - NCT07440225RecruitingPhase 2/Phase 3
Testing a new drug for wet macular degeneration
This trial tests a new medicine called EYE201/MK-8748 for people who have wet age-related macular degeneration (a condition where abnormal blood vessels grow under the retina). It's for those who haven't had treatment before and were diagnosed recently.
Scottsdale, ArizonaAges 50 years+ - NCT07776522RecruitingPhase 2
Gene therapy for wet age-related macular degeneration
This trial tests a one-time gene therapy injection under the retina for people with wet age-related macular degeneration (AMD), which causes blurry vision from abnormal blood vessels. It aims to reduce the need for frequent eye injections by delivering a treatment that may help the eye produce its own medicine.
Beijing, Beijing MunicipalityAges 50–85 - NCT07441642RecruitingPhase 2
Study of FWY003 for geographic atrophy in age-related macular degeneration
This trial tests an investigational drug FWY003 against a placebo to see if it can slow or stop the progression of geographic atrophy, a form of advanced age-related macular degeneration that causes vision loss.
Huntington Beach, CaliforniaAges 50 years+ - NCT05197270RecruitingPhase 1/Phase 2
Gene therapy for wet age-related macular degeneration
This study tests a new gene therapy called 4D-150 for people with wet age-related macular degeneration (AMD). It aims to reduce the need for frequent anti-VEGF injections by delivering a long-lasting treatment into the eye.
Phoenix, ArizonaAges 50 years+ - NCT06847542RecruitingPhase 3
Study of a refillable eye implant for wet AMD
This trial tests a refillable eye implant (PDS) that slowly releases medication to treat wet age-related macular degeneration (nAMD). It aims to see if replacing the implant every 36 weeks works as well as regular eye injections.
InnsbruckAges 50 years+ - NCT07770828RecruitingPhase 3
Gene therapy for advanced dry age-related macular degeneration
This trial tests an experimental gene therapy, OCU410, for people with geographic atrophy, an advanced form of dry AMD that causes blind spots in the center of vision. The study aims to see if this treatment can slow down the progression of the disease and help preserve remaining vision.
Phoenix, ArizonaAges 55 years+ - NCT07007065RecruitingPhase 3
Study of a gene therapy for wet age-related macular degeneration
This trial tests a one-time gene therapy injection for wet AMD that may reduce the need for regular eye injections. It is for people who have already responded to anti-VEGF injections but want a longer-lasting treatment.
Mesa, ArizonaAges 50 years+ - NCT06541704RecruitingPhase 3
Study of pozelimab with cemdisiran for geographic atrophy
This trial tests a combination of two study drugs (pozelimab and cemdisiran) given as a shot under the skin to slow the progression of geographic atrophy, a type of advanced dry age-related macular degeneration that causes blind spots in central vision.
Chandler, ArizonaAges 50–85 - NCT04853251RecruitingPhase 4
Study of corneal cells after a ranibizumab eye implant
This trial checks how well corneal endothelial cells (cells that help keep the cornea clear) do in people with neovascular age-related macular degeneration (nAMD) who are treated with a port-delivery implant that releases ranibizumab. It also helps doctors understand whether this method changes corneal health and stays safe while controlling the eye disease.
Mesa, ArizonaAges 50 years+ - NCT06765980RecruitingPhase 1/Phase 2
Study of KRIYA-825 for geographic atrophy in age-related macular degeneration
This trial tests an experimental drug called KRIYA-825 (also known as VV-14295) for people with geographic atrophy, a late stage of dry age-related macular degeneration that causes vision loss. The study aims to see if the treatment is safe and can help slow the progression of the disease.
Erie, PennsylvaniaAges 55–80 - NCT07317934RecruitingPhase 3
Gene therapy for wet age-related macular degeneration
This study tests a one-time gene therapy called LX102 for wet age-related macular degeneration (AMD). It may reduce the need for frequent eye injections and help preserve vision.
Hefei, AnhuiAges 50–80 - NCT07496567RecruitingPhase 2/Phase 3
Study of EYE201 for wet age-related macular degeneration
This trial tests a new medicine, EYE201, for people with wet age-related macular degeneration (AMD) that has not been treated before. The study will see if this drug can help improve vision and slow down vision loss.
Gilbert, ArizonaAges 50 years+ - NCT06031727RecruitingEarly Phase 1
CRISPR gene therapy for wet age-related macular degeneration
This trial tests a new CRISPR-based treatment for wet age-related macular degeneration (AMD). It aims to stop vision loss by targeting the cause of abnormal blood vessel growth in the eye. This study is for people who have already tried anti-VEGF injections but might not be responding well enough.
Shanghai, Shanghai MunicipalityAges 50–80 - NCT04985487Recruiting
Safety follow-up for brolucizumab in neovascular AMD
This study tracks the real-world safety of brolucizumab in adults with neovascular age-related macular degeneration (nAMD). If you’re already prescribed this medicine, the study may help confirm it continues to be safe and well-tolerated over time.
Daegu, Dalseo GuAges 18–100 - NCT05562947RecruitingPhase 3
Ranibizumab port implant for wet macular degeneration in Chinese adults
This Phase 3 study tests whether a small eye implant that delivers medicine on a schedule (the port delivery system) with ranibizumab works better and safely in people with wet age-related macular degeneration. It’s designed for patients who have already been treated recently with anti-VEGF injections and need continued control.
BeijingAges 50 years+ - NCT06213038RecruitingPhase 1
Study of SKG0106 for wet age-related macular degeneration
This study tests a new medicine called SKG0106, given as an injection into the eye, for people with wet age-related macular degeneration (AMD). It aims to see if it is safe and effective in treating the leaky blood vessels that cause vision loss.
BeijingAges 50 years+ - NCT07640997Recruiting
Real-world study of aflibercept for age-related macular degeneration
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
Beijing, Beijing MunicipalityAges 50 years+ - NCT07695207RecruitingPhase 3
Testing SMZ1 with ranibizumab for wet macular degeneration
This trial tests a new medicine called SMZ1 combined with ranibizumab (a standard treatment) for people with wet macular degeneration. It may help improve vision by targeting the cause of the disease more effectively.
Seoul, SeoulAges 50 years+ - NCT07053358RecruitingEarly Phase 1
Gene therapy for wet AMD
This trial tests a new gene therapy (LX111) for people with wet age-related macular degeneration (AMD) who have already been helped by standard anti-VEGF injections. The goal is to see if one dose of LX111 can reduce the need for frequent eye injections.
ShanghaiAges 50 years+ - NCT07516132RecruitingPhase 3
Long-term safety study of axitinib implant for wet macular degeneration
This study follows people who completed an earlier 2-year trial of OTX-TKI, a small implant placed in the eye to treat wet age-related macular degeneration (a condition causing vision loss). Researchers want to make sure the treatment remains safe over time.
Bakersfield, CaliforniaAges 50 years+
Hear when a new Neovascular Age-related Macular Degeneration trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Neovascular Age-related Macular Degeneration trials by city
Studies with a site in or near these metro areas.
Neovascular Age-related Macular Degeneration trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for neovascular age-related macular degeneration?
- Yes. Clin2 currently lists 82 recruiting neovascular age-related macular degeneration studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neovascular age-related macular degeneration trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neovascular age-related macular degeneration trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Neovascular Age-Related Macular Degeneration (nAMD)
- Neovascular (Wet) Age-Related Macular Degeneration
- Age-Related Macular Degeneration
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- Age-related Macular Degeneration (ARMD)
- Exudative Age-Related Macular Degeneration
- Wet Age-related Macular Degeneration (wAMD)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.